Read by QxMD icon Read

Carl H June

Courtney B Rubin, Rosalie Elenitsas, Laura Taylor, Simon F Lacey, Irina Kulikovskaya, Minnal Gupta, Jan J Melenhorst, Alison Loren, Noelle Frey, Carl H June, David Porter, Misha Rosenbach
No abstract text is available yet for this article.
November 2016: Journal of the American Academy of Dermatology
Michael M Lederman, Paula M Cannon, Judith S Currier, Carl H June, Hans Peter Kiem, Daniel R Kuritzkes, Sharon R Lewin, David M Margolis, Joseph M McCune, John W Mellors, Timothy W Schacker, Rafick P Sekaly, Pablo Tebas, Bruce D Walker, Daniel C Douek
With the advent and stunning success of combination antiretroviral therapy (ART) to prolong and improve quality of life for persons with HIV infection, HIV research has been afforded the opportunity to pivot towards studies aimed at finding "a cure." The mere idea that cure of HIV might be possible has energized researchers and the community towards achieving this goal. Funding agencies, both governmental and private, have targeted HIV cure as a high priority; many in the field have responded to these initiatives and the cure research agenda is robust...
2016: Pathogens & Immunity
Julie C Fitzgerald, Scott L Weiss, Shannon L Maude, David M Barrett, Simon F Lacey, J Joseph Melenhorst, Pamela Shaw, Robert A Berg, Carl H June, David L Porter, Noelle V Frey, Stephan A Grupp, David T Teachey
OBJECTIVE: Initial success with chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through multicenter trials. Cytokine release syndrome, the most severe toxicity, presents a novel critical illness syndrome with limited data regarding diagnosis, prognosis, and therapy. We sought to characterize the timing, severity, and intensive care management of cytokine release syndrome after chimeric antigen receptor-modified T cell therapy...
September 14, 2016: Critical Care Medicine
Joseph R Pierce, Kathleen N Beasley, Amanda J Centi, Dennis E Scofield, Charles H Negus, Rachel K Evans, Carl M Maresh, William J Kraemer, Bradley C Nindl
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
Marco Ruella, David M Barrett, Saad S Kenderian, Olga Shestova, Ted J Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F Lacey, Jan J Melenhorst, Jennifer J D Morrissette, David A Christian, Christopher A Hunter, Michael Kalos, David L Porter, Carl H June, Stephan A Grupp, Saar Gill
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients. Developing approaches to preventing and treating antigen-loss escapes would therefore represent a vertical advance in the field. Here, we found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration...
October 3, 2016: Journal of Clinical Investigation
Andrew D Fesnak, Carl H June, Bruce L Levine
The immune system evolved to distinguish non-self from self to protect the organism. As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge. This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumour microenvironment. The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed. Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy...
August 23, 2016: Nature Reviews. Cancer
J Y Zhang, Q Wang, S S Lin, J W Chen, H L Zhong, D Q Ca, Z G Chen
OBJECTIVE: To investigate the incidence and features of myopia in children aged 7 to 14 years. METHODS: Cross-sectional study. A total of 2 226 children (2 226 eyes) aged 7 to 14 years were selected from school during June 2012 and January 2015. Refraction was measured by fast cycloplegic retinoscopy. SPSS16.0 was used to analyze the data. Ocular refractive parameters, including axial length (AL), corneal power, anterior chamber depth, and white to white, were measured by IOLMaster (version 5...
July 2016: [Zhonghua Yan Ke za Zhi] Chinese Journal of Ophthalmology
Christopher L Jenkins, Mark L Bagarazzi, Hans-Peter Kiem, Arnold J Levine, Dale Ando, Carl H June, Tony Reid, David W Emery
No abstract text is available yet for this article.
August 2016: Molecular Therapy: the Journal of the American Society of Gene Therapy
Yunjie Lu, Keli L Hippen, Amanda L Lemire, Jian Gu, Weizhi Wang, Xuhao Ni, Parvathi Ranganathan, Bruce L Levine, James L Riley, Carl H June, Laurence A Turka, David H Munn, Ramiro Garzon, Ling Lu, Bruce R Blazar
CD4(+)CD25(+)FoxP3(+) thymic-derived regulatory T cells (tTregs) are indispensable for maintaining immune system equilibrium. Adoptive transfer of tTregs is an effective means of suppressing graft-versus-host disease (GVHD) in murine models and in early human clinical trials. Tumor necrosis factor receptor-associated factor 6 (TRAF6), an ubiquitin-conjugating enzyme that mediates nuclear factor κB (NF-κB) activation, plays an essential role in modulating regulatory T cell survival and function. MicroRNAs (miRNAs) are noncoding RNAs, which mediate RNA silencing and posttranscriptional gene repression...
September 8, 2016: Blood
Marco Ruella, Carl H June
Genetic redirection of T lymphocytes allows us to unleash these potent cellular immune effectors against cancer. Chimeric antigen receptor (CAR) T cells are the best-in-class example that genetic engineering of T cells can lead to deep and durable responses, as has been shown in several clinical trials for CD19+ B cell malignancies. As a consequence, in the last few years, several academic institutions and commercial partners have started developing anti-CD19 CAR T cell products. Although most of these T cell products are highly effective in vivo, basic differences among them can generate different performance characteristics and thereby impact their long-term clinical outcome...
October 2016: Current Hematologic Malignancy Reports
Emese Zsiros, Denarda Dangaj, Carl H June, Lana E Kandalaft, George Coukos
Tumor barriers preventing T-cell homing and engraftment should be neutralized during cancer immunotherapy. We recently discovered that ovarian cancer expresses quasi-universal chemokines that can support T-cell homing. Furthermore, T cells elicited by whole tumor antigen dendritic-cell vaccines express cognate chemokine receptors which are upregulated by CD3/CD28 costimulation.
May 2016: Oncoimmunology
Karen D LaRoché, Carl R Hinkson, Brett A Thomazin, Paula K Minton-Foltz, David J Carlbom
BACKGROUND: In the United States, care for COPD patients is frequently delivered by respiratory therapists (RTs). After implementing a therapist-driven protocol for COPD treatment, we sought to improve identification of COPD patients. We hypothesized that using an electronic medical record screening tool to identify subjects with COPD combined with a therapist-driven protocol would positively impact length of stay (LOS) and readmission rates. METHODS: Utilizing the electronic medical record to search the provider's admission notes for the terms COPD/Asthma, a report was generated...
September 2016: Respiratory Care
David R Hooper, Kevin E Schill, Catherine Saenz, Emily R Martini, Shawn D Flanagan, Tunde K Szivak, William H DuPont, Brian C Focht, Jeff S Volek, Carl M Maresh, William J Kraemer
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
Carl H Russell, James B Robinson
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
William H DuPont, William J Kraemer, Bradley C Nindl, Jakob L Vingren, Barry A Spiering, Shawn D Flanagan, Lydia K Caldwell, Tunde K Szivak, Emily C Barnhart, Emily C Borden, Carl M Maresh
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
Marinus Winters, Carl C Barten, Rens Teeuwen, Eric W P Bakker, Maarten H Moen, Frank J G Backx, Adam Weir
No abstract text is available yet for this article.
May 2016: Medicine and Science in Sports and Exercise
Peter S Vosler, Jason I Kass, Eric W Wang, Carl H Snyderman
OBJECTIVE: We compare the management of patients with severe epistaxis before and after the implementation a clinical care pathway (CCP) to standardize care, minimize hospital stay, and decrease cost. STUDY DESIGN: Single prospective analysis with historical control. SETTING: Tertiary academic hospital. SUBJECTS AND METHODS: Patients treated for epistaxis between October 2012 to December 2013 were compared with a prospective analysis of patients treated for severe epistaxis after implementation of a CCP from June 2014 to February 2015...
June 28, 2016: Otolaryngology—Head and Neck Surgery
Carl H June
Genetic engineering of patient T cells with chimeric antigen receptors (CAR T cells) provides a powerful tool for inducing remissions in patients with various cancers derived from B cells. Challenges stemming from the inability to control the CAR T cells once given pose significant safety concerns. An article in Cancer Immunology Research presents an approach to circumvent this issue. Cancer Immunol Res; 4(8); 643. ©2016 AACRSee article by Sakemura et al., p. 658.
August 2016: Cancer Immunology Research
Avery D Posey, Robert D Schwab, Alina C Boesteanu, Catharina Steentoft, Ulla Mandel, Boris Engels, Jennifer D Stone, Thomas D Madsen, Karin Schreiber, Kathleen M Haines, Alexandria P Cogdill, Taylor J Chen, Decheng Song, John Scholler, David M Kranz, Michael D Feldman, Regina Young, Brian Keith, Hans Schreiber, Henrik Clausen, Laura A Johnson, Carl H June
Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate robust responses against lineage restricted, non-essential targets in hematologic cancers. However, in solid tumors, the full potential of CAR T cell therapy is limited by the availability of cell surface antigens with sufficient cancer-specific expression. The majority of CAR targets have been normal self-antigens on dispensable hematopoietic tissues or overexpressed shared antigens. Here, we established that abnormal self-antigens can serve as targets for tumor rejection...
June 21, 2016: Immunity
Vijay G Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, James Capobianchi, Colleen A Callahan, Christoph T Ellebrecht, Amrom E Obstfeld, Simon F Lacey, Jan J Melenhorst, Farzana Nazimuddin, Wei-Ting Hwang, Shannon L Maude, Mariusz A Wasik, Adam Bagg, Stephen Schuster, Michael D Feldman, David L Porter, Stephen A Grupp, Carl H June, Michael C Milone
The mechanisms underlying the maintenance of long-lasting humoral immunity are not well understood. Studies in mice indicate that plasma cells (PCs) can survive up to a lifetime, even in the absence of regeneration by B cells, implying the presence of long-lived PCs as a mechanism for long-lasting immunity. Evidence from humans treated with anti-CD20, which depletes circulating B cells, also suggests B-cell-independent long-term survival of some PCs. On the other hand, antibody responses may be sustained solely by short-lived PCs with repopulation from clonally related memory B cells...
July 21, 2016: Blood
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"